Navigation Links
PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients
Date:10/24/2008

al trials that evaluate long-term clinical benefit for CF patients."

Patients with CF lack adequate levels of the CFTR protein, a chloride channel which is required for normal function of the lung, pancreas, liver and other organs. Nonsense mutations are single-point alterations in the genetic code that when transcribed into mRNA prematurely stop the mRNA translation process, preventing production of a full-length, functional protein. Patients with nonsense-mutation CF make virtually no CFTR protein and thus often have a more severe form of CF. Nonsense mutations are responsible for approximately 10 percent of the cases of CF worldwide.

By inducing the production of functional CFTR, PTC124 addresses one of the underlying genetic defects responsible for CF. Earlier studies of PTC124 in adults with CF evaluated nasal transepithelial potential difference (TEPD) as a surrogate for the presence and activity of the CFTR protein. Across a variety of studies, TEPD assessments showed statistically significant improvements of mean CFTR-dependent chloride secretion in the airways.

European Phase 2a Study Results

The multicenter, randomized, open-label Phase 2a study demonstrated that treatment with PTC124 caused improvements in CFTR-mediated chloride conductance and in apical expression of CFTR protein in nasal epithelium. The study enrolled 30 children ages 6 to 18 years to evaluate the activity, safety and pharmacokinetic activity of PTC124 in pediatric patients. All of the patients had nonsense-mutation CF, pathological lung infection, and CF-induced pancreatic insufficiency. In a cross-over design testing 14 days of PTC124 at two dose levels, patients were randomized to receive either the lower or higher dose first. PTC124 treatment across both dose levels was associated with a statistically significant (p=0.03) increase in the proportion of epithelial cells showing cell surface CFTR protein. PTC124 also induced significantly improved CFTR-media
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
4. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
5. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
6. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
7. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
8. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
9. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
10. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
11. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015 Today, humanity takes a ... the singularity, and fat-free cronuts: 1-800 CONTACTS announces their new ... in just two taps. Two taps. New contacts. ... The app also features LensGauge which helps keep ... when you need to reorder. "Since our inception, ...
(Date:4/24/2015)... April 24, 2015  A new study shows an "alarming ... drugs used to slow the progression of multiple sclerosis or ... by researchers at Oregon Health & Science University (OHSU) and ... the number of MS drugs in the marketplace over the ... stabilized costs for patients who use those drugs. Researchers found ...
(Date:4/24/2015)... S.C. , April 24, 2015  Span-America ... plans to release its fiscal 2015 second quarter ... regular trading. The company will conduct ... Friday, May 1, to review the company,s financial and ... 2015.  A live broadcast of the conference call ...
Breaking Medicine Technology:Attention: We live in the future. Order contact lenses from your wrist with the 1-800 CONTACTS app for Apple Watch 2Researchers find alarming rise in cost of MS drugs over past two decades 2Researchers find alarming rise in cost of MS drugs over past two decades 3Researchers find alarming rise in cost of MS drugs over past two decades 4
... influenza,transmission patterns in the Southern Hemisphere and ... finding that,each season influenza travels from low ... populated centers. Their work, funded by the,Fogarty ... Institutes,of Health (NIH), can improve planning for ...
... - An overexpressed protein,protects human pancreatic cancer ... of the body's natural defenses against,out-of-control cell growth, ... Cancer Center report in the March issue of ... by the abbreviation,TG2, previously has been found by ...
Cached Medicine Technology:Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 2Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 3Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 2Protein Found to Shield Pancreatic Cancer Cells from,Self-Destruction 3
(Date:4/25/2015)... 25, 2015 By definition, a CIO’s responsibility ... the enterprise relying on their judgement and expertise to keep ... according to an article published in National Mortgage News ... be doing a disservice to their responsibilities by focusing too ... t’s are crossed when it comes to company policy and ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 Parker and Sons ... and cooling, has spiked in Arizona alongside the growing economy. ... additional forty employees for April to help account for the ... forty employees in April is something we are enthusiastic about. ... said Paul Kelly, president at Parker and Sons. , Indeed, ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI ... event in the nation! This year, on May 5th, 2015, ... to take DI Day on the road by supporting the ... ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants ... the change by stating, "The first Twin Cities DI Day ...
(Date:4/24/2015)... 24, 2015 As the nation recognizes ... unique sacrifices of these young men and women, the ... Veterans and their Families” presents a special training session ... to gain a better understanding of the effect of ... For those – civilian and military – who provide ...
(Date:4/24/2015)... 2015 Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ... federal multidistrict litigation underway in U.S. District Court, ... the parties involved in the proceeding submitted a ... other things, preparation for the litigation’s upcoming bellwether ... plaintiffs and defendants have conducted depositions of non-party ...
Breaking Medicine News(10 mins):Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... transplants after removing small cancerous and benign masses from ... December issue of the urology journal BJUI. The ... of Maryland School of Medicine in Baltimore, could offer ... as well as increasing the supply of viable organs. ...
... Nutra Pharma ... the Food and Drug Administration (FDA). This registration is considered the final step required by ... the treatment of chronic pain. , ... Plantation, FL (Vocus) December 7, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology ...
... ... Changes in Industry Standards and Compliance Requirements , ... (PRWEB) December 7, 2009 -- BridgeGate ... the launch of its new integration technology training program, which will kick off ...
... in comparison study , SUNDAY, Dec. 6 (HealthDay ... therapy for prostate cancer are best controlled by ... according to a new study. , Androgen suppression ... prostate cancer, but about 80 percent of patients ...
... older anti-clotting drug, with fewer hassles, study finds , MONDAY, ... dabigatran etexilate may be just as effective in preventing dangerous ... for doctors and patients to manage, a new study finds. ... in Europe; it is not yet approved for use in ...
... ... offer top-of-the-line implementation services to Talyst’s clients in the acute care industry. ... (PRWEB) ... of the American Society of Health-System Pharmacists in Las Vegas, Talyst announced a ...
Cached Medicine News:Health News:Controversial kidney transplant technique could provide lifeline for very ill patients 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 2Health News:BridgeGate International Announces New Integration and Interoperability Training Program 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 4Health News:Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: